Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Werewolf Therapeutics stock | $15.37

Learn how to easily invest in Werewolf Therapeutics stock.

Werewolf Therapeutics Inc is a biotechnology business based in the US. Werewolf Therapeutics shares (HOWL) are listed on the NASDAQ and all prices are listed in US Dollars. Werewolf Therapeutics employs 31 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Werewolf Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HOWL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Werewolf Therapeutics stock price (NASDAQ: HOWL)

Use our graph to track the performance of HOWL stocks over time.

Werewolf Therapeutics shares at a glance

Information last updated 2021-10-24.
Latest market close$15.37
52-week range$11.23 - $21.67
50-day moving average $17.03
200-day moving average $15.82
Wall St. target price$26.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-36.98

Buy Werewolf Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Werewolf Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Werewolf Therapeutics price performance over time

Historical closes compared with the close of $15.37 from 2021-10-26

1 week (2021-10-20) -5.42%
1 month (2021-09-27) -11.92%
3 months (2021-07-27) -18.50%
6 months (2021-04-23) N/A
1 year (2020-10-23) N/A
2 years (2019-10-23) N/A
3 years (2018-10-23) N/A
5 years (2016-10-23) N/A

Werewolf Therapeutics financials

Gross profit TTM $0
Return on assets TTM -23.72%
Return on equity TTM -30.39%
Profit margin 0%
Book value $6.59
Market capitalisation $446.3 million

TTM: trailing 12 months

Shorting Werewolf Therapeutics shares

There are currently 663,251 Werewolf Therapeutics shares held short by investors – that's known as Werewolf Therapeutics's "short interest". This figure is 2% down from 676,614 last month.

There are a few different ways that this level of interest in shorting Werewolf Therapeutics shares can be evaluated.

Werewolf Therapeutics's "short interest ratio" (SIR)

Werewolf Therapeutics's "short interest ratio" (SIR) is the quantity of Werewolf Therapeutics shares currently shorted divided by the average quantity of Werewolf Therapeutics shares traded daily (recently around 15243.645139048). Werewolf Therapeutics's SIR currently stands at 43.51. In other words for every 100,000 Werewolf Therapeutics shares traded daily on the market, roughly 43510 shares are currently held short.

To gain some more context, you can compare Werewolf Therapeutics's short interest ratio against those of similar companies.

However Werewolf Therapeutics's short interest can also be evaluated against the total number of Werewolf Therapeutics shares, or, against the total number of tradable Werewolf Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Werewolf Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Werewolf Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0347% of the tradable shares (for every 100,000 tradable Werewolf Therapeutics shares, roughly 35 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Werewolf Therapeutics.

Find out more about how you can short Werewolf Therapeutics stock.

Werewolf Therapeutics share dividends

We're not expecting Werewolf Therapeutics to pay a dividend over the next 12 months.

Werewolf Therapeutics overview

Werewolf Therapeutics, Inc. , a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, with the help of its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics in the news

There are no recent company news

Frequently asked questions

What percentage of Werewolf Therapeutics is owned by insiders or institutions?
Currently 12.923% of Werewolf Therapeutics shares are held by insiders and 81.501% by institutions.
How many people work for Werewolf Therapeutics?
Latest data suggests 31 work at Werewolf Therapeutics.
When does the fiscal year end for Werewolf Therapeutics?
Werewolf Therapeutics's fiscal year ends in December.
Where is Werewolf Therapeutics based?
Werewolf Therapeutics's address is: 1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
What is Werewolf Therapeutics's ISIN number?
Werewolf Therapeutics's international securities identification number is: US95075A1079

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site